ClinicalTrials.gg
CompletedNCT06319482Updated Oct 16, 2026

The Adherence of Proactive Sleep Apnea Therapy

An interventional study of Proactive CPAP Therapy and Conventional APAP Therapy in Obstructive Sleep Apnea, sponsored by NovaResp Technologies Inc. Completed at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by NovaResp Technologies Inc · Not applicable, Interventional, and Treatment

How we know

Updated Oct 16, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 133 studies in Sleep Apnea, Obstructive with a site in Canada — 22 open to participants now, 31 under way, 4 of them phase 3. Sleep Apnea, Obstructive · Canada.

Enrollment
37th of 102
96 · median 60
Started
2024
with 5 others
No phase
70 of 133
9 open now
Registered
117th of 133
by date
Lead sponsor
3 of 133
NovaResp Technologies Inc

Among the 133 studies in Sleep Apnea, Obstructive with a site in Canada, this one is the 37th largest by enrollment of the 102 interventional ones that give a count, is one of 6 that started in 2024, is one of 70 with no phase, and was the 117th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

22 of the 133 studies in Sleep Apnea, Obstructive with a site in Canada are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Sleep Apnea, Obstructive with a site in Canada, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the adherence to Positive Airway Pressure (PAP) therapy for newly diagnosed Obstructive Sleep Apnea (OSA) patients. The main question(s) it aims to answer are:

  1. To compare the adherence of proactive therapy and conventional Automatic-PAP (APAP) therapy short-term (3 months) and long-term (12 months) for newly diagnosed OSA patients.
  2. To compare health outcomes (AHI, nightly usage, leak, and patient-reported outcomes) between proactive therapy and conventional APAP therapy.
Read the detailed description

This is a double-blind, randomized controlled superiority trial on newly diagnosed patients with obstructive sleep apnea. Each participant will be provided with a APAP device. The devices assigned to the test group will be modified to deliver the proactive therapy using Artificial Intelligence (AI). Devices assigned to the control group will deliver the conventional APAP therapy. A sleep technician will be in regular contact with participants and track the time spent interacting with each participant. At the conclusion of the first 3 months of the trial, participants who are acceptant to therapy will be asked if they would like to continue participating for an additional 9 months. Data will be collected by the PAP device and a series of self-reported questionnaires.

03

Conditions studied

  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have a new diagnosis of moderate or severe OSA (i.e., AHI > 15 events/hour).
  • Must be 18-70 years old.
  • No history of self-reported, uncontrolled, severe cardiovascular or neurological issues.
  • Must be able to comply with all study requirements as outlined in the consent form.
  • Must be able to follow the directions of the study doctor and research team.
  • Must be able to understand English and be willing to provide .

Exclusion criteria

Exclusion Criteria:

  • Prior use of PAP machines.
  • Subjects actively using bi-level PAP or require oxygen therapy.
  • Subjects who are medically complicated or who are medically unstable ( i.e., cancer, dementia, unstable cardiac or respiratory disease, or unstable psychiatric illness).
  • Potential sleep apnea complications that, in the opinion of the clinician, may affect the health and safety of the participant.
  • Inability or unwillingness to given written .
  • Neuromuscular disease, hypoglossal-nerve palsy, severe restrictive or obstructive pulmonary disease, moderate-to-severe pulmonary arterial hypertension, severe valvular heart disease, class III or IV heart failure, recent myocardial infarction or severe cardiac arrhythmias (within the past 6 months), persistent uncontrolled hypertension despite medication use, active psychiatric disease, and coexisting non-respiratory sleep disorders that would confound functional sleep assessment.
  • Pregnancy, planning to attempt to become pregnant, or breastfeeding.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    Proactive CPAP Therapy (Intervention)

    Patients will undergo CPAP enabled with proactive therapy.

    Device: Proactive CPAP Therapy

  • Active comparator
    Conventional APAP Therapy (Control)

    Patients will undergo conventional APAP therapy.

    Device: Conventional APAP Therapy

Interventions

  • DeviceProactive CPAP Therapy

    CPAP machine uses Artificial Intelligence to make predictions and preventions of future apneic events to auto-adjust pressure.

  • DeviceConventional APAP Therapy

    CPAP machine relies on the detection of respiratory events to determine how to react and auto-adjust pressure.

06

What researchers measure

Primary outcomes

  1. Adherence

    Calculated as at least 70% compliance (at least 4 hrs), in 30 days

    Time frame: 3-12 months

Secondary outcomes

  1. Apnea-Hypopnea Index

    Calculated as the mean number of apnea and hypopnea events throughout the night in events/hr.

    Time frame: 3-12 months

  2. CPAP Therapy Usage

    Calculated as the mean device usage by the patient throughout the night.

    Time frame: 3-12 months

  3. Self-assessed sleep outcomes

    Patients will be requested to fill out a questionnaire to help evaluate their sleepiness before and after therapy. Scale: Epworth Sleepiness Scale on a 7-point scale, higher values meaning worse outcome.

    Time frame: 3-12 months

  4. Self-assessed functional outcomes

    Patients will be requested to fill out a questionnaire to help evaluate their functional outcomes of sleep before and after therapy. Scale: Functional Outcomes of Sleep Questionnaire on a 7-point scale, higher values meaning better outcomes.

    Time frame: 3-12 months

07

Study locations

1 site
  • NovaResp Technologies Inc.
    Halifax, Nova Scotia B3H 4H5, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Apr 2026, 21 months.

Of 118 industry-sponsored interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's 21 months is above that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Jun 2025 → Apr 2026 and completion Jun 2025 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2024
First posted
Mar 20, 2024
StartActual
Jun 16, 2024
Primary completionActual
Apr 10, 2026was Jun 2025
CompletionActual
Apr 10, 2026was Jun 2025
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 16, 2026
Primary completion
Jun 16, 2025→Apr 10, 2026 (actual)
Oct 16, 2026
Study completion
Jun 16, 2025→Apr 10, 2026 (actual)
Oct 16, 2026
Enrollment
200 (estimated)→96 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Recruiting→Completed
    Primary completion Jun 16, 2025→Apr 10, 2026 (now actual)
    Study completion Jun 16, 2025→Apr 10, 2026 (now actual)
    Enrollment 200 (estimated)→96 (actual)
    + 4 other changes: oversight details, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06319482
Lead sponsor
NovaResp Technologies Inc
Responsible party
Sponsor
First posted
Mar 20, 2024
Start date
Jun 16, 2024
Primary completion
Apr 10, 2026
Completion
Apr 10, 2026
Last update
Oct 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion